Abstract: This non-oriented electrical steel sheet includes a base material having a chemical composition including Si: 3.7 to 4.8%, wherein a recrystallization rate is less than 100% in terms of an area fraction, the following Formula (i) and Formula (ii) are satisfied, and the tensile strength is more than 700 MPa. 4.3?Si+sol. Al+0.5×Mn?4.9??(i) (B50(0°)+2×B50(45°)+B50(90°))/4?1.

Abstract: Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals.

Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

Abstract: Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals.

Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

Abstract: To provide a method for simply measuring ethanolamine phosphate in a sample, and a reagent, kit, program and the like useful in the method. A measurement method of ethanolamine phosphate includes a first step of adding an enzyme, which can catalyze a reaction that forms acetaldehyde from ethanolamine phosphate, to a sample, and conducting a first enzymatic reaction to form acetaldehyde, phosphoric acid and ammonia; and a second step of quantifying at least one of the resultant acetaldehyde, phosphoric acid and ammonia to determine an amount of the ethanolamine phosphate in the measurement sample.

Abstract: The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof:

Abstract: The present invention provides compounds represented by formulas (I) to (VI) or pharmaceutically acceptable salts thereof.

Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:

Abstract: To provide a method for simply measuring ethanolamine phosphate in a sample, and a reagent, kit, program and the like useful in the method. A measurement method of ethanolamine phosphate includes a first step of adding an enzyme, which can catalyze a reaction that forms acetaldehyde from ethanolamine phosphate, to a sample, and conducting a first enzymatic reaction to form acetaldehyde, phosphoric acid and ammonia; and a second step of quantifying at least one of the resultant acetaldehyde, phosphoric acid and ammonia to determine an amount of the ethanolamine phosphate in the measurement sample.

Abstract: A method for predicting options of depression treatment drugs includes (a) measuring a phosphoethanolamine (PEA) level in blood collected from a patient suspected of depression, (b) measuring whether the blood PEA level of the patient is lower than a reference value or not, wherein if the measured value of the patient is lower than values of healthy persons, the patient suffers from depression exhibiting a decreased PEA level as an indicator, and (c) predicting options of depression treatment drugs on the basis of the presence or absence of decreased blood PEA level in the patient. Thus, PEA, which is a biomarker of depression, can be directly linked to treatment.

Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:

Abstract: To provide a method for simply measuring ethanolamine phosphate in a sample, and a reagent, kit, program and the like useful in the method. A measurement method of ethanolamine phosphate includes a first step of adding an enzyme, which can catalyze a reaction that forms acetaldehyde from ethanolamine phosphate, to a sample, and conducting a first enzymatic reaction to form acetaldehyde, phosphoric acid and ammonia; and a second step of quantifying at least one of the resultant acetaldehyde, phosphoric acid and ammonia to determine an amount of the ethanolamine phosphate in the measurement sample.

Abstract: A method for treating depression using a biomarker includes measuring a level of phosphoethanolamine in a blood sample collected from a subject, comparing the level of phosphoethanolamine in the blood sample with a predetermined threshold, in response to the level of phosphoethanolamine in the blood sample being below the predetermined threshold, determining that the subject requires a treatment for depression, and treating the subject determined to suffer from depression.

Abstract: To provide a method for simply measuring ethanolamine phosphate in a sample, and a reagent, kit, program and the like useful in the method. A measurement method of ethanolamine phosphate includes a first step of adding an enzyme, which can catalyze a reaction that forms acetaldehyde from ethanolamine phosphate, to a sample, and conducting a first enzymatic reaction to form acetaldehyde, phosphoric acid and ammonia; and a second step of quantifying at least one of the resultant acetaldehyde, phosphoric acid and ammonia to determine an amount of the ethanolamine phosphate in the measurement sample.

Abstract: A method for treating depression using a biomarker includes measuring a level of phosphoethanolamine in a blood sample collected from a subject, comparing the level of phosphoethanolamine in the blood sample with a predetermined threshold, in response to the level of phosphoethanolamine in the blood sample being below the predetermined threshold, determining that the subject requires a treatment for depression, and treating the subject determined to suffer from depression.

Abstract: Provided is a method for using low molecular weight compounds found in the body as a biomarker for diagnosing depression. Specifically, more than one compound selected from a group comprising the following are used: ADP-ribose, ATP, ADP, AMP, serotonin, tryptophan, kynurenine, SDMA (symmetrical dimethylarginine), threonine, glyceric acid, serine, N-acetylaspartic acid, glutamic acid, trigonelline, creatine, 2-methylserine, sphingosine, homovanillic acid, piperidine, sulfoxidized methionine, pipecolic acid, sphinganine, gamma-butyrobetaine, guanidinoacetic acid, isobutyric acid, creatinine, sarcosine, 3-methylbutyric acid, nicotinamide, betaine, ornithine, carnitine, ethanolamine, phosphoethanolamine, taurine, hypotaurine, aspartic acid, methionine, and tyrosine.

Abstract: The present invention relates to novel diagnostic markers for kidney disease and the use thereof.

Abstract: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.